Screening of Chlamydia trachomatis urogenital infections among the male and female population of the Republic of Macedonia

Miroslav S. Spasovski, Liljana J. Simjanovska, Vaso Taleski, Nada Petrova, Liljana Lazetic, Zaneta Popeska, Charlotte A Gaydos, Thomas C Quinn, Georgi D. Efremovt

Research output: Contribution to journalArticle

Abstract

Background: Noninvasive urine screening for Chlamydia trachomatis infections offers a valuable public health tool, that could be of vast importance in Chlamydia control programs. Objective: The goal was to determine the prevalence of C. trachomatis infections among a sexually active population, to define the epidemiological factors associated with it, and to develop potential selective screening strategies among asymptomatic individuals in the Republic of Macedonia, using a highly sensitive and specific DNA amplification method for C. trachomatis. Study design: A total of 1435 urine samples, divided into two main groups: asymptomatic individuals (n = 1210) and symptomatic patients (n = 225), were tested. Samples from the asymptomatic group were collected during routine screening programs, while the symptomatic group consisted of patients with symptoms of urogenital tract infection, attending sexually transmitted diseases (STD) clinics. The presence of C. trachomatis was determined using commercial AMPLICOR C. trachomatis Assay (Roche Diagnostic Systems, Inc., Branchburg, NJ, USA). Results: The prevalence of C. trachomatis infections among different groups was: recruits 0%, soldiers 0.4%, policemen 3.5%, clerks 4.6%, pregnant women 4%, and students 4.4%. The average prevalence for both groups (asymptomatic and symptomatic) was 2.3% [95% confidence interval (CI): 1.5-3.1%]. The average prevalence for the asymptomatic group was 1.6% (95% CI: 0.8-2.4%), while the average prevalence for the symptomatic group was 6.2% (95% CI: 3.1-9.3%) which were significantly different (P = 0.00003). Conclusion: Testing first void urine specimens by AMPLICOR C. trachomatis assay is a highly sensitive and specific method for diagnosing C. trachomatis infections in men and women. This method provides health care workers and public health officials with a new molecular amplification assay that uses noninvasive urine specimens for population-based screening purposes. The prevalence of C. trachomatis was relatively low among asymptomatic individuals. However, selective screening strategies arc highly recommended for testing the student population in the Republic of Macedonia.

Original languageEnglish (US)
Pages (from-to)427-430
Number of pages4
JournalJournal of the European Academy of Dermatology and Venereology
Volume19
Issue number4
DOIs
StatePublished - Jul 2005
Externally publishedYes

Fingerprint

Macedonia (Republic)
Chlamydia trachomatis
Chlamydia Infections
Infection
Population
Urine
Confidence Intervals
Public Health
Students
Chlamydia
Military Personnel
Sexually Transmitted Diseases
Pregnant Women

Keywords

  • Amplicor assay
  • Chlamydia trachomatis
  • DNA PCR analysis
  • Screening
  • Urine samples

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

Screening of Chlamydia trachomatis urogenital infections among the male and female population of the Republic of Macedonia. / Spasovski, Miroslav S.; Simjanovska, Liljana J.; Taleski, Vaso; Petrova, Nada; Lazetic, Liljana; Popeska, Zaneta; Gaydos, Charlotte A; Quinn, Thomas C; Efremovt, Georgi D.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 19, No. 4, 07.2005, p. 427-430.

Research output: Contribution to journalArticle

Spasovski, Miroslav S. ; Simjanovska, Liljana J. ; Taleski, Vaso ; Petrova, Nada ; Lazetic, Liljana ; Popeska, Zaneta ; Gaydos, Charlotte A ; Quinn, Thomas C ; Efremovt, Georgi D. / Screening of Chlamydia trachomatis urogenital infections among the male and female population of the Republic of Macedonia. In: Journal of the European Academy of Dermatology and Venereology. 2005 ; Vol. 19, No. 4. pp. 427-430.
@article{47f6733ef055456aa8ee81aa2e15425a,
title = "Screening of Chlamydia trachomatis urogenital infections among the male and female population of the Republic of Macedonia",
abstract = "Background: Noninvasive urine screening for Chlamydia trachomatis infections offers a valuable public health tool, that could be of vast importance in Chlamydia control programs. Objective: The goal was to determine the prevalence of C. trachomatis infections among a sexually active population, to define the epidemiological factors associated with it, and to develop potential selective screening strategies among asymptomatic individuals in the Republic of Macedonia, using a highly sensitive and specific DNA amplification method for C. trachomatis. Study design: A total of 1435 urine samples, divided into two main groups: asymptomatic individuals (n = 1210) and symptomatic patients (n = 225), were tested. Samples from the asymptomatic group were collected during routine screening programs, while the symptomatic group consisted of patients with symptoms of urogenital tract infection, attending sexually transmitted diseases (STD) clinics. The presence of C. trachomatis was determined using commercial AMPLICOR C. trachomatis Assay (Roche Diagnostic Systems, Inc., Branchburg, NJ, USA). Results: The prevalence of C. trachomatis infections among different groups was: recruits 0{\%}, soldiers 0.4{\%}, policemen 3.5{\%}, clerks 4.6{\%}, pregnant women 4{\%}, and students 4.4{\%}. The average prevalence for both groups (asymptomatic and symptomatic) was 2.3{\%} [95{\%} confidence interval (CI): 1.5-3.1{\%}]. The average prevalence for the asymptomatic group was 1.6{\%} (95{\%} CI: 0.8-2.4{\%}), while the average prevalence for the symptomatic group was 6.2{\%} (95{\%} CI: 3.1-9.3{\%}) which were significantly different (P = 0.00003). Conclusion: Testing first void urine specimens by AMPLICOR C. trachomatis assay is a highly sensitive and specific method for diagnosing C. trachomatis infections in men and women. This method provides health care workers and public health officials with a new molecular amplification assay that uses noninvasive urine specimens for population-based screening purposes. The prevalence of C. trachomatis was relatively low among asymptomatic individuals. However, selective screening strategies arc highly recommended for testing the student population in the Republic of Macedonia.",
keywords = "Amplicor assay, Chlamydia trachomatis, DNA PCR analysis, Screening, Urine samples",
author = "Spasovski, {Miroslav S.} and Simjanovska, {Liljana J.} and Vaso Taleski and Nada Petrova and Liljana Lazetic and Zaneta Popeska and Gaydos, {Charlotte A} and Quinn, {Thomas C} and Efremovt, {Georgi D.}",
year = "2005",
month = "7",
doi = "10.1111/j.1468-3083.2005.01204.x",
language = "English (US)",
volume = "19",
pages = "427--430",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Screening of Chlamydia trachomatis urogenital infections among the male and female population of the Republic of Macedonia

AU - Spasovski, Miroslav S.

AU - Simjanovska, Liljana J.

AU - Taleski, Vaso

AU - Petrova, Nada

AU - Lazetic, Liljana

AU - Popeska, Zaneta

AU - Gaydos, Charlotte A

AU - Quinn, Thomas C

AU - Efremovt, Georgi D.

PY - 2005/7

Y1 - 2005/7

N2 - Background: Noninvasive urine screening for Chlamydia trachomatis infections offers a valuable public health tool, that could be of vast importance in Chlamydia control programs. Objective: The goal was to determine the prevalence of C. trachomatis infections among a sexually active population, to define the epidemiological factors associated with it, and to develop potential selective screening strategies among asymptomatic individuals in the Republic of Macedonia, using a highly sensitive and specific DNA amplification method for C. trachomatis. Study design: A total of 1435 urine samples, divided into two main groups: asymptomatic individuals (n = 1210) and symptomatic patients (n = 225), were tested. Samples from the asymptomatic group were collected during routine screening programs, while the symptomatic group consisted of patients with symptoms of urogenital tract infection, attending sexually transmitted diseases (STD) clinics. The presence of C. trachomatis was determined using commercial AMPLICOR C. trachomatis Assay (Roche Diagnostic Systems, Inc., Branchburg, NJ, USA). Results: The prevalence of C. trachomatis infections among different groups was: recruits 0%, soldiers 0.4%, policemen 3.5%, clerks 4.6%, pregnant women 4%, and students 4.4%. The average prevalence for both groups (asymptomatic and symptomatic) was 2.3% [95% confidence interval (CI): 1.5-3.1%]. The average prevalence for the asymptomatic group was 1.6% (95% CI: 0.8-2.4%), while the average prevalence for the symptomatic group was 6.2% (95% CI: 3.1-9.3%) which were significantly different (P = 0.00003). Conclusion: Testing first void urine specimens by AMPLICOR C. trachomatis assay is a highly sensitive and specific method for diagnosing C. trachomatis infections in men and women. This method provides health care workers and public health officials with a new molecular amplification assay that uses noninvasive urine specimens for population-based screening purposes. The prevalence of C. trachomatis was relatively low among asymptomatic individuals. However, selective screening strategies arc highly recommended for testing the student population in the Republic of Macedonia.

AB - Background: Noninvasive urine screening for Chlamydia trachomatis infections offers a valuable public health tool, that could be of vast importance in Chlamydia control programs. Objective: The goal was to determine the prevalence of C. trachomatis infections among a sexually active population, to define the epidemiological factors associated with it, and to develop potential selective screening strategies among asymptomatic individuals in the Republic of Macedonia, using a highly sensitive and specific DNA amplification method for C. trachomatis. Study design: A total of 1435 urine samples, divided into two main groups: asymptomatic individuals (n = 1210) and symptomatic patients (n = 225), were tested. Samples from the asymptomatic group were collected during routine screening programs, while the symptomatic group consisted of patients with symptoms of urogenital tract infection, attending sexually transmitted diseases (STD) clinics. The presence of C. trachomatis was determined using commercial AMPLICOR C. trachomatis Assay (Roche Diagnostic Systems, Inc., Branchburg, NJ, USA). Results: The prevalence of C. trachomatis infections among different groups was: recruits 0%, soldiers 0.4%, policemen 3.5%, clerks 4.6%, pregnant women 4%, and students 4.4%. The average prevalence for both groups (asymptomatic and symptomatic) was 2.3% [95% confidence interval (CI): 1.5-3.1%]. The average prevalence for the asymptomatic group was 1.6% (95% CI: 0.8-2.4%), while the average prevalence for the symptomatic group was 6.2% (95% CI: 3.1-9.3%) which were significantly different (P = 0.00003). Conclusion: Testing first void urine specimens by AMPLICOR C. trachomatis assay is a highly sensitive and specific method for diagnosing C. trachomatis infections in men and women. This method provides health care workers and public health officials with a new molecular amplification assay that uses noninvasive urine specimens for population-based screening purposes. The prevalence of C. trachomatis was relatively low among asymptomatic individuals. However, selective screening strategies arc highly recommended for testing the student population in the Republic of Macedonia.

KW - Amplicor assay

KW - Chlamydia trachomatis

KW - DNA PCR analysis

KW - Screening

KW - Urine samples

UR - http://www.scopus.com/inward/record.url?scp=21744454336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21744454336&partnerID=8YFLogxK

U2 - 10.1111/j.1468-3083.2005.01204.x

DO - 10.1111/j.1468-3083.2005.01204.x

M3 - Article

VL - 19

SP - 427

EP - 430

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 4

ER -